The burgeoning landscape of medication for excess body fat and type 2 metabolic disorder is currently witnessing considerable excitement surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 target agonists, significant differences in their pharmacological profiles and clinical investigation results are emergin

Arriving in the field of weight management management, retatrutide presents a distinct approach. Different from many existing medications, retatrutide works as a double agonist, at once targeting both GLP peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This simultaneous activation encourages several beneficial ef